ELAN VS MRK Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividend

Performance

ELAN
10/100

ELAN returned -9.80% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

MRK
100/100

MRK returned 1.78% in the last 12 months. Based on SPY's performance of -13.80%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

ELAN
64/100

11 analysts offer 12-month price targets for ELAN. Together, they have an average target of 27, the most optimistic target put ELAN at 37 within 12-months and the most pessimistic has ELAN at 18.

MRK
68/100

21 analysts offer 12-month price targets for MRK. Together, they have an average target of 113.88, the most optimistic target put MRK at 294 within 12-months and the most pessimistic has MRK at 80.

Technicals

ELAN
89/100

ELAN receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

MRK
10/100

MRK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

ELAN
100/100

ELAN has missed earnings 1 times in the last 20 quarters.

MRK
53/100

MRK has missed earnings 3 times in the last 20 quarters.

Profit

ELAN
22/100

Out of the last 20 quarters, ELAN has had 6 profitable quarters and has increased their profits year over year on 2 of them.

MRK
66/100

Out of the last 20 quarters, MRK has had 17 profitable quarters and has increased their profits year over year on 7 of them.

Volatility

ELAN
45/100

ELAN has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

MRK
52/100

MRK has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Dividend

ELAN

"Dividend" not found for ELAN

MRK
100/100

MRK's most recent dividend was $0.47 per share, based on a share price of $101.35. It was a payout ratio of 69.90% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Elanco Animal Health Incorporated Common Stock Summary

New York Stock Exchange / ELAN
Healthcare
Drug Manufacturers - Specialty & Generic
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Merck & Co., Inc. Summary

New York Stock Exchange / MRK
Healthcare
Drug Manufacturers - General
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.